Trial Profile
A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 [lapatinib] in Combination With Trastuzumab [Herceptin]
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 03 Aug 2012 Actual end date (1 Feb 2005) added as reported by ClinicalTrials.gov.
- 21 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2005 New trial record.